Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.
We’re hosting a webinar on March 12 called Cross-Border M&A: Opportunities and Issues. As a run-up to it, here’s a peek at what U.S. health care companies have bought overseas in 2015, excluding the typical pharma/biotech rights and licensing deals. We’ve seen 13 acquisitions of foreign companies so far, better than the 10 recorded in the same […]
With only four deals announced in January, it seemed as if M&A in the medical devices sector was drying up. Not quite, as 11 announcements surfaced in February. The largest came last week, as Sorin SpA (MIL: SRN) agreed to merge with Houston-based Cyberonics Inc. (NASDAQ: CYBX). The all-stock transaction produces a combined equity value […]